| Sonstiges: |
- Nachgewiesen in: MEDLINE
- Sprachen: English
- Publication Type: Journal Article; Review
- Language: English
- [Horm Mol Biol Clin Investig] 2021 Feb 08; Vol. 42 (2), pp. 223-234. <i>Date of Electronic Publication: </i>2021 Feb 08.
- MeSH Terms: Polymorphism, Single Nucleotide* ; Thyroid Neoplasms / *genetics ; DNA Repair ; Gene Expression Regulation, Neoplastic ; Genetic Predisposition to Disease ; Genetic Variation ; Humans ; Iran / epidemiology ; Risk Factors ; Thyroid Neoplasms / epidemiology
- References: Deandrea, M, Gallone, G, Veglio, M, Balsamo, A, Grassi, A, Sapelli, S, et al.. Thyroid cancer histotype changes as observed in a major general hospital in a 21-year period. J Endocrinol Invest 1997;20:52–8. https://doi.org/10.1007/bf03347976. ; Feldt-Rasmussen, U. Iodine and cancer. Thyroid 2001;11:483–6. https://doi.org/10.1089/105072501300176435. ; Kohler, BA, Ward, E, McCarthy, BJ, Schymura, MJ, Ries, LA, Eheman, C, et al.. Annual report to the nation on the status of cancer, 1975–2007, featuring tumors of the brain and other nervous system. J Natl Cancer Inst 2011;103:714–36. https://doi.org/10.1093/jnci/djr077. ; Jemal, A, Bray, F, Center, MM, Ferlay, J, Ward, E, Forman, D. Global cancer statistics. CA A Cancer J Clin 2011;61:69–90. https://doi.org/10.3322/caac.20107. ; Chen, AY, Jemal, A, Ward, EM. Increasing incidence of differentiated thyroid cancer in the United States, 1988–2005. Cancer: Interdiscipl Int J Am Cancer Soc 2009;115:3801–7. https://doi.org/10.1002/cncr.24416. ; Segev, DL, Umbricht, C, Zeiger, MA. Molecular pathogenesis of thyroid cancer. Surg Oncol 2003;12:69–90. https://doi.org/10.1016/s0960-7404(03)00037-9. ; Torlontano, M, Attard, M, Crocetti, U, Tumino, S, Bruno, R, Costante, G, et al.. Follow-up of low risk patients with papillary thyroid cancer: role of neck ultrasonography in detecting lymph node metastases. J Clin Endocrinol Metabol 2004;89:3402–7. https://doi.org/10.1210/jc.2003-031521. ; Xu, L, Port, M, Landi, S, Gemignani, F, Cipollini, M, Elisei, R, et al.. Obesity and the risk of papillary thyroid cancer: a pooled analysis of three case–control studies. Thyroid: Off J Am Thyroid Assoc 2014;24:966–74. https://doi.org/10.1089/thy.2013.0566. ; Oberman, B, Khaku, A, Camacho, F, Goldenberg, D. Relationship between obesity, diabetes and the risk of thyroid cancer. Am J Otolaryngol 2015;36:535–41. https://doi.org/10.1016/j.amjoto.2015.02.015. ; Bann, DV, Goyal, N, Camacho, F, Goldenberg, D. Increasing incidence of thyroid cancer in the Commonwealth of Pennsylvania. JAMA Otolaryngol Head Neck Surg 2014;140:1149–56. https://doi.org/10.1001/jamaoto.2014.1709. ; Lehrer, S, Rosenzweig, KE. Cold climate is a risk factor for thyroid cancer. Clin Thyroidol 2014;26:273–6. https://doi.org/10.1089/ct.2014;26.273-276. ; Memon, A, De Gonzalez, AB, Luqmani, Y, Suresh, A. Family history of benign thyroid disease and cancer and risk of thyroid cancer. Eur J Canc 2004;40:754–60. https://doi.org/10.1016/j.ejca.2003.12.011. ; Ma, J, Huang, M, Wang, L, Ye, W, Tong, Y, Wang, H. Obesity and risk of thyroid cancer: evidence from a meta-analysis of 21 observational studies. Med Sci Mon Int Med J Exp Clin Res 2015;21:283. ; Hong, K-S, Son, J-W, Ryu, OH, Choi, M-G, Hong, JY, Lee, SJ. Cardiac effects of thyrotropin oversuppression with levothyroxine in young women with differentiated thyroid cancer. Int J Endocrinol 2016;2016:6. doi:https://doi.org/10.1155/2016/9846790. ; Khayamzadeh, M, Khayamzadeh, M, Tadayon, N, Salmanian, R, Zham, H, Razzaghi, Z, et al.. Survival of thyroid cancer and social determinants in Iran. Asian Pac J Cancer Prev 2011;12:95–8. ; Karkoobi, Y, Moradi, G, Sharifi, P, Ghafoori, S. Assessment of thyroid cancer risk factors in Kurdistan province. Sci J Kurdistan Univ Med Sci 2018;23:10–8. ; Morris, LG, Myssiorek, D. Improved detection does not fully explain the rising incidence of well-differentiated thyroid cancer: a population-based analysis. Am J Surg 2010;200:454–61. https://doi.org/10.1016/j.amjsurg.2009.11.008. ; Davies, L, Welch, HG. Current thyroid cancer trends in the United States. JAMA Otolaryngol Head Neck Surg 2014;140:317–22. https://doi.org/10.1001/jamaoto.2014.1. ; Erichsen, HC, Chanock, SJ. SNPs in cancer research and treatment. Br J Canc 2004;90:747–51. https://doi.org/10.1038/sj.bjc.6601574. ; Mehta, RG, Mehta, RR. Vitamin D and cancer. J Nutr Biochem 2002;13:252–64. https://doi.org/10.1016/s0955-2863(02)00183-3. ; Ordonez-Moran, P, Larriba, MJ, Pendas-Franco, N, Aguilera, O, Gonzalez-Sancho, JM, Munoz, A. Vitamin D and cancer: an update of in vitro and in vivo data. Front Biosci 2005;10:2723–49. https://doi.org/10.2741/1731. ; Slattery, ML. Vitamin D receptor gene (VDR) associations with cancer. Nutr Rev 2007;65:S102–S4. https://doi.org/10.1301/nr.2007.aug.s102-s104. ; Hutchinson, PE, Osborne, JE, Lear, JT, Smith, AG, Bowers, PW, Morris, PN, et al.. Vitamin D receptor polymorphisms are associated with altered prognosis in patients with malignant melanoma. Clin Canc Res 2000;6:498–504. ; Ntais, C, Polycarpou, A, Ioannidis, JPA. Vitamin D receptor gene polymorphisms and risk of prostate cancer: a meta-analysis. Cancer Epidemiol Biomark Prev 2003;12:1395–402. ; Ye, WZ, Reis, AF, Velho, G. Identification of a novel Tru9 I polymorphism in the human vitamin D receptor gene. J Hum Genet 2000;45:56–7. https://doi.org/10.1007/s100380050011. ; Penna-Martinez, M, Ramos-Lopez, E, Stern, J, Hinsch, N, Hansmann, M-L, Selkinski, I, et al.. Vitamin D receptor polymorphisms in differentiated thyroid carcinoma. Thyroid : Off J Am Thyroid Assoc 2009;19:623–8. https://doi.org/10.1089/thy.2008.0388. ; Haghpanah, V, Ghaffari, SH, Rahimpour, P, Abbasi, A, Saeedi, M, Pak, H, et al.. Vitamin D receptor gene polymorphisms in patients with thyroid cancer. Gene Ther Mol Biol B 2007;11:299–304. ; Horvatic Herceg, G, Herceg, D, Kralik, M, Kulic, A, Bence-Zigman, Z, Tomic-Brzac, H, et al.. Urokinase plasminogen activator and its inhibitor type-1 as prognostic factors in differentiated thyroid carcinoma patients. Otolaryngology-Head Neck Surg (Tokyo) 2013;149:533–40. https://doi.org/10.1177/0194599813496374. ; Ulisse, S, Baldini, E, Sorrenti, S, Barollo, S, Gnessi, L, Catania, A, et al.. High expression of the urokinase plasminogen activator and its cognate receptor associates with advanced stages and reduced disease-free interval in papillary thyroid carcinoma. J Clin Endocrinol Metabol 2011;96:504–8. https://doi.org/10.1210/jc.2010-1688. ; Mashiko, S, Kitatani, K, Toyoshima, M, Ichimura, A, Dan, T, Usui, T, et al.. Inhibition of plasminogen activator inhibitor-1 is a potential therapeutic strategy in ovarian cancer. Canc Biol Ther 2015;16:253–60. https://doi.org/10.1080/15384047.2014.1001271. ; Torres-Carrillo, N, Magdalena Torres-Carrillo, N, Vázquez-Del Mercado, M, Rangel-Villalobos, H, Parra-Rojas, I, Sánchez-Enríquez, S, et al.. Distribution of --844 G/A and Hind III C/G PAI-1 polymorphisms and plasma PAI-1 levels in Mexican subjects: comparison of frequencies between populations. Clin Appl Thromb Hemost 2008;14:220–6. https://doi.org/10.1177/1076029607304747. ; Palmirotta, R, Ferroni, P, Savonarola, A, Martini, F, Ciatti, F, Laudisi, A, et al.. Prognostic value of pre-surgical plasma PAI-1 (plasminogen activator inhibitor-1) levels in breast cancer. Thromb Res 2009;124:403–8. https://doi.org/10.1016/j.thromres.2009.02.014. ; Zhang, H, Dong, P, Yang, X, Liu, Z. Plasminogen activator inhibitor-1 4G/5G polymorphism is associated with coronary artery disease risk: a meta-analysis. Int J Clin Exp Med 2014;7:3777–88. ; Lewy-Trenda, I. Estrogen and progesterone receptors in neoplastic and non-neoplastic thyroid lesions. Pol J Pathol 2002;53:67–72. ; Money, SR, Muss, W, Thelmo, WL, Boeckl, O, Pimpl, W, Kaindl, H, et al.. Immunocytochemical localization of estrogen and progesterone receptors in human thyroid. Surgery 1989;106:975–9. ; Mazzaferri, EL, Young, RL, Oertel, JE, Kemmerer, WT, Page, CP. Papillary thyroid carcinoma: the impact of therapy in 576 patients. Medicine (Baltim) 1977;56:171–96. https://doi.org/10.1097/00005792-197705000-00001. ; Liu, J, Chen, G, Meng, X-Y, Liu, Z-H, Dong, S. Serum levels of sex hormones and expression of their receptors in thyroid tissue in female patients with various types of thyroid neoplasms. Pathol Res Pract 2014;210:830–5. https://doi.org/10.1016/j.prp.2014.09.002. ; Vasudevan, N, Ogawa, S, Pfaff, D. Estrogen and thyroid hormone receptor interactions: physiological flexibility by molecular specificity. Physiol Rev 2002;82:923–44. https://doi.org/10.1152/physrev.00014.2002. ; Shick, PC, Riordan, GP, Foss, RD. Estrogen and progesterone receptors in salivary gland adenoid cystic carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1995;80:440–4. https://doi.org/10.1016/s1079-2104(05)80338-5. ; Varley, JM. Germline TP53 mutations and Li-Fraumeni syndrome. Hum Mutat 2003;21:313–20. https://doi.org/10.1002/humu.10185. ; Noma, C, Miyoshi, Y, Taguchi, T, Tamaki, Y, Noguchi, S. Association of p53 genetic polymorphism (Arg72Pro) with estrogen receptor positive breast cancer risk in Japanese women. Canc Lett 2004;210:197–203. https://doi.org/10.1016/j.canlet.2004.03.031. ; Pietsch, E, Humbey, O. Polymorphisms in the p53 pathway. Philadelphia, PA, USA: Division of Medical Science, Fox Chase Cancer Center; 2006. ; Khadang, B, Fattahi, MJ, Talei, A, Dehaghani, AS, Ghaderi, A. Polymorphism of TP53 codon 72 showed no association with breast cancer in Iranian women. Canc Genet Cytogenet 2007;173:38–42. https://doi.org/10.1016/j.cancergencyto.2006.09.010. ; Boltze, C, Roessner, A, Landt, O, Szibor, R, Peters, B, Schneider-Stock, R. Homozygous proline at codon 72 of p53 as a potential risk factor favoring the development of undifferentiated thyroid carcinoma. Int J Oncol 2002;21:1151–4. ; Granja, F, Morari, J, Morari, EC, Correa, LAC, Assumpção, LVM, Ward, LS. Proline homozygosity in codon 72 of p53 is a factor of susceptibility for thyroid cancer. Canc Lett 2004;210:151–7. https://doi.org/10.1016/j.canlet.2004.01.016. ; Aral, C, Akkiprik, M, Kaya, H, Ataizi-Çelikel, C, Caglayan, S, Ozisik, G, et al.. Mitochondrial DNA common deletion is not associated with thyroid, breast and colorectal tumors in Turkish patients. Genet Mol Biol 2010;33:1–4. https://doi.org/10.1590/S1415-47572009005000102. ; Reis, AAS, Silva, DM, Curado, MP, da Cruz, AD. Involvement of CYP1A1, GST, 72TP53 polymorphisms in the pathogenesis of thyroid nodules. Genet Mol Res 2010;9:2222–9. https://doi.org/10.4238/vol9-4gmr807. ; Landers, JE, Cassel, SL, George, DL. Translational enhancement of mdm2 oncogene expression in human tumor cells containing a stabilized wild-type p53 protein. Canc Res 1997;57:3562–8. ; Wade, M, Wang, YV, Wahl, GM. The p53 orchestra: Mdm2 and Mdmx set the tone. Trends Cell Biol 2010;20:299–309. https://doi.org/10.1016/j.tcb.2010.01.009. ; Wynendaele, J, Böhnke, A, Leucci, E, Nielsen, SJ, Lambertz, I, Hammer, S, et al.. An illegitimate microRNA target site within the 3’ UTR of MDM4 affects ovarian cancer progression and chemosensitivity. Canc Res 2010;70:9641–9. https://doi.org/10.1158/0008-5472.can-10-0527. ; McEvoy, J, Ulyanov, A, Brennan, R, Wu, G, Pounds, S, Zhang, J, et al.. Analysis of MDM2 and MDM4 single nucleotide polymorphisms, mRNA splicing and protein expression in retinoblastoma. PloS One 2012;7:e42739-e. https://doi.org/10.1371/journal.pone.0042739. ; Eischen, CM, Lozano, G. The Mdm network and its regulation of p53 activities: a rheostat of cancer risk. Hum Mutat 2014;35:728–37. https://doi.org/10.1002/humu.22524. ; Senturk, E, Manfredi, JJ. Mdm2 and tumorigenesis: evolving theories and unsolved mysteries. Gene Canc 2012;3:192–8. https://doi.org/10.1177/1947601912457368. ; Thomasova, D, Mulay, SR, Bruns, H, Anders, H-J. p53-independent roles of MDM2 in NF-κB signaling: implications for cancer therapy, wound healing, and autoimmune diseases. Neoplasia 2012;14:1097–101. https://doi.org/10.1593/neo.121534. ; Zhang, F, Xu, L, Wei, Q, Song, X, Sturgis, EM, Li, G. Significance of MDM2 and P14ARF polymorphisms in susceptibility to differentiated thyroid carcinoma. Surgery 2013;153:711–7. https://doi.org/10.1016/j.surg.2012.11.009. ; Altieri, DC. Survivin in apoptosis control and cell cycle regulation in cancer. Prog Cell Cycle Res 2003;5:447–52. ; Altieri, DC. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 2003;22:8581. https://doi.org/10.1038/sj.onc.1207113. ; Li, F. Role of survivin and its splice variants in tumorigenesis. Br J Canc 2005;92:212. https://doi.org/10.1038/sj.bjc.6602340. ; Tirrò, E, Consoli, ML, Massimino, M, Manzella, L, Frasca, F, Sciacca, L, et al.. Altered expression of c-IAP1, survivin, and Smac contributes to chemotherapy resistance in thyroid cancer cells. Canc Res 2006;66:4263–72. https://doi.org/10.1158/0008-5472.can-05-3248. ; Selemetjev, SA, Savin, SB, Paunovic, IR, Tatic, SB, Cvejic, D. Changes in the expression pattern of apoptotic molecules (galectin-3, Bcl-2, Bax, survivin) during progression of thyroid malignancy and their clinical significance. Wien Klin Wochenschr 2015;127:337–44. https://doi.org/10.1007/s00508-014-0674-6. ; Chen, Z, Liu, N, Zhu, G, Dralle, H, Hoang-Vu, C. Targeting of the anti-apoptotic gene survivin in human thyroid carcinoma. Int J Mol Med 2012;30:465–72. https://doi.org/10.3892/ijmm.2012.1046. ; Pannone, G, Santoro, A, Pasquali, D, Zamparese, R, Mattoni, M, Russo, G, et al.. The role of survivin in thyroid tumors: differences of expression in well-differentiated, non–well-differentiated, and anaplastic thyroid cancers. Thyroid 2014;24:511–9. https://doi.org/10.1089/thy.2013.0196. ; Mahaney, BL, Meek, K, Lees-Miller, SP. Repair of ionizing radiation-induced DNA double-strand breaks by non-homologous end-joining. Biochem J 2009;417:639–50. https://doi.org/10.1042/bj20080413. ; Mani, RS, Yu, Y, Fang, S, Lu, M, Fanta, M, Zolner, AE, et al.. Dual modes of interaction between XRCC4 and polynucleotide kinase/phosphatase implications for nonhomologous end joining. J Biol Chem 2010;285:37619–29. https://doi.org/10.1074/jbc.m109.058719. ; Siraj, A, Al-Rasheed, M, Ibrahim, M, Siddiqui, K, Al-Dayel, F, Al-Sanea, O, et al.. RAD52 polymorphisms contribute to the development of papillary thyroid cancer susceptibility in Middle Eastern population. J Endocrinol Invest 2008;31:893–9. https://doi.org/10.1007/bf03346438. ; Gomes, BC, Silva, SN, Azevedo, AP, Manita, I, Gil, OM, Ferreira, TC, et al.. The role of common variants of non-homologous end-joining repair genes XRCC4, LIG4 and Ku80 in thyroid cancer risk. Oncol Rep 2010;24:1079–85. ; Chiang, F-Y, Wu, C-W, Hsiao, P-J, Kuo, W-R, Lee, K-W, Lin, J-C, et al.. Association between polymorphisms in DNA base excision repair genes XRCC1, APE1, and ADPRT and differentiated thyroid carcinoma. Clin Canc Res 2008;14:5919–24. https://doi.org/10.1158/1078-0432.ccr-08-0906. ; Zhu, Q, Bian, J, Shen, Q, Jiang, F, Tang, H, Zhang, H, et al.. Genetic polymorphisms in X-ray repair cross-complementing gene 1 and susceptibility to papillary thyroid carcinoma. Zhonghua Liuxingbingxue Zazhi 2004;25:702–5. ; Ho, T, Li, G, Lu, J, Zhao, C, Wei, Q, Sturgis, EM. Association of XRCC1 polymorphisms and risk of differentiated thyroid carcinoma: a case–control analysis. Thyroid 2009;19:129–35. https://doi.org/10.1089/thy.2008.0153. ; Ryu, RA, Tae, K, Min, HJ, Jeong, JH, Cho, SH, Lee, SH, et al.. XRCC1 polymorphisms and risk of papillary thyroid carcinoma in a Korean sample. J Kor Med Sci 2011;26:991–5. https://doi.org/10.3346/jkms.2011.26.8.991. ; Okamura, H, Tsutsui, H, Komatsu, T, Yutsudo, M, Hakura, A, Tanimoto, T, et al.. Cloning of a new cytokine that induces IFN-γ production by T cells. Nature 1995;378:88. https://doi.org/10.1038/378088a0. ; Takiyama, Y, Miyokawa, N, Tokusashi, Y, Ito, K, Kato, S, Kimura, S, et al.. Thyroid-stimulating hormone induces interleukin-18 gene expression in FRTL-5 cells: immunohistochemical detection of interleukin-18 in autoimmune thyroid disease. Thyroid 2002;12:935–43. https://doi.org/10.1089/105072502320908268. ; Liu, Z, Wang, H, Xiao, W, Wang, C, Liu, G, Hong, T. Thyrocyte interleukin‐18 expression is up‐regulated by interferon‐γ and may contribute to thyroid destruction in Hashimoto’s thyroiditis. Int J Exp Pathol 2010;91:420–5. https://doi.org/10.1111/j.1365-2613.2010.00715.x. ; Kalina, U, Ballas, K, Koyama, N, Kauschat, D, Miething, C, Arnemann, J, et al.. Genomic organization and regulation of the human interleukin‐18 gene: FRONTLINES. Scand J Immunol 2000;52:525–30. https://doi.org/10.1046/j.1365-3083.2000.00836.x. ; Giedraitis, V, He, B, Huang, W-X, Hillert, J. Cloning and mutation analysis of the human IL-18 promoter: a possible role of polymorphisms in expression regulation. J Neuroimmunol 2001;112:146–52. https://doi.org/10.1016/s0165-5728(00)00407-0. ; Haghshenas, MR, Hosseini, SV, Mahmoudi, M, Saberi‐Firozi, M, Farjadian, S, Ghaderi, A. IL‐18 serum level and IL‐18 promoter gene polymorphism in Iranian patients with gastrointestinal cancers. J Gastroenterol Hepatol 2009;24:1119–22. https://doi.org/10.1111/j.1440-1746.2009.05791.x. ; Razmkhah, M, Doroudchi, M, Mojtahedi, Z, Ghaderi, A. Association of Interleukin18 gene promoter polymorphisms with breast cancer. Neoplasma 2009;56:1. ; Farjadfar, A, Mojtahedi, Z, Ghayumi, MA, Erfani, N, Haghshenas, MR, Ghaderi, A. Interleukin-18 promoter polymorphism is associated with lung cancer: a case-control study. Acta Oncol 2009;48:971–6. https://doi.org/10.1080/02841860902878145. ; Walker, LS, Sansom, DM. The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses. Nat Rev Immunol 2011;11:852. https://doi.org/10.1038/nri3108. ; Ghaderi, A. CTLA4 gene variants in autoimmunity and cancer: a comparative review. Iran J Immunol 2011;8:127–49. ; Karabon, L, Kosmaczewska, A, Bilinska, M, Pawlak, E, Ciszak, L, Jedynak, A, et al.. The CTLA‐4 gene polymorphisms are associated with CTLA‐4 protein expression levels in multiple sclerosis patients and with susceptibility to disease. Immunology 2009;128:e787–e96. https://doi.org/10.1111/j.1365-2567.2009.03083.x. ; Ligers, A, Teleshova, N, Masterman, T, Huang, W, Hillert, J. CTLA-4 gene expression is influenced by promoter and exon 1 polymorphisms. Gene Immun 2001;2:145. https://doi.org/10.1038/sj.gene.6363752. ; Chang, D-F, Chen, X-H, Huang, J, Sun, Y-M, Zhu, D-Y, Xu, Z-Q. CTLA-4 gene polymorphisms associate with efficacy of postoperative radioiodine-131 for differentiated thyroid carcinoma. Future Oncol 2017;13:1057–68. https://doi.org/10.2217/fon-2016-0399. ; Okazaki, T, Maeda, A, Nishimura, H, Kurosaki, T, Honjo, T. PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proc Natl Acad Sci 2001 98:13866–71. https://doi.org/10.1073/pnas.231486598. ; French, JD, Kotnis, GR, Said, S, Raeburn, CD, McIntyre, RCJr, Klopper, JP, et al.. Programmed death-1+ T cells and regulatory T cells are enriched in tumor-involved lymph nodes and associated with aggressive features in papillary thyroid cancer. J Clin Endocrinol Metabol 2012;97:E934–E43. https://doi.org/10.1210/jc.2011-3428. ; Mojtahedi, Z, Mohmedi, M, Rahimifar, S, Erfani, N, Hosseini, SV, Ghaderi, A. Programmed death-1 gene polymorphism (PD-1.5 C/T) is associated with colon cancer. Gene 2012;508:229–32. https://doi.org/10.1016/j.gene.2012.07.059. ; Mojtahedi, Z, Erfani, N, Haghshenas, MR, Hosseini, SV, Ghaderi, A. Association of FoxP3/Scurfin germline polymorphism (C-2383T/rs3761549) with colorectal cancer. Ann Colorectal Res 2013;1:12–6. https://doi.org/10.17795/acr-11478. ; Song, X, Zhong, H, Wu, Q, Wang, M, Zhou, J, Zhou, Y, et al.. Association between SNPs in microRNA machinery genes and gastric cancer susceptibility, invasion, and metastasis in Chinese Han population. Oncotarget 2017;8:86435. https://doi.org/10.18632/oncotarget.21199. ; Erler, P, Keutgen, XM, Crowley, MJ, Zetoune, T, Kundel, A, Kleiman, D, et al.. Dicer expression and microRNA dysregulation associate with aggressive features in thyroid cancer. Surgery 2014;156:1342–50. https://doi.org/10.1016/j.surg.2014.08.007. ; Leaderer, D, Hoffman, AE, Zheng, T, Fu, A, Weidhaas, J, Paranjape, T, et al.. Genetic and epigenetic association studies suggest a role of microRNA biogenesis gene exportin-5 (XPO5) in breast tumorigenesis. Int J Mol Epidemiol Genet 2011;2:9. ; Wen, J, Gao, Q, Wang, N, Zhang, W, Cao, K, Zhang, Q, et al.. Association of microRNA-related gene XPO5 rs11077 polymorphism with susceptibility to thyroid cancer. Medicine (Baltim) 2017;96. https://doi.org/10.1097/md.0000000000006351. ; Tang, R, Yang, C, Ma, X, Wang, Y, Luo, D, Huang, C, et al.. MiR-let-7a inhibits cell proliferation, migration, and invasion by down-regulating PKM2 in gastric cancer. Oncotarget 2016;7:5972. https://doi.org/10.18632/oncotarget.6821. ; Pan, W, Wu, C, Su, Z, Duan, Z, Li, L, Mi, F, et al.. Genetic polymorphisms of non-coding RNAs associated with increased head and neck cancer susceptibility: a systematic review and meta-analysis. Oncotarget 2017;8:62508. https://doi.org/10.18632/oncotarget.20096. ; Wang, Y, Wei, T, Xiong, J, Chen, P, Wang, X, Zhang, L, et al.. Association between genetic polymorphisms in the promoter regions of let-7 and risk of papillary thyroid carcinoma: a case-control study. Medicine (Baltim) 2015;94:e1879. doi:https://doi.org/10.1097/md.0000000000001879. ; He, J, Zou, Y, Liu, X, Zhu, J, Zhang, J, Zhang, R, et al.. Association of common genetic variants in pre-microRNAs and neuroblastoma susceptibility: a two-center study in Chinese children. Mol Ther Nucleic Acids 2018;11:1–8. https://doi.org/10.1016/j.omtn.2018.01.003. ; Hashemi, M. MicroRNAs: promising potential targets for cancer treatment. Gene Cell Tissue 2016;3:e42864. doi:https://doi.org/10.17795/gct-42864. ; Chen, P, Sun, R, Pu, Y, Bai, P, Yuan, F, Liang, Y, et al.. Pri-miR-34b/C and Tp-53 polymorphisms are associated with the susceptibility of papillary thyroid carcinoma: a case–control study. Medicine (Baltim) 2015;94. https://doi.org/10.1097/md.0000000000001536. ; Dehghan, R, Hosseinpour Feizi, MA, Pouladi, N, Adampourezare, M, Farajzadeh, D. The TP53 intron 6 G13964C polymorphism and risk of thyroid and breast cancer development in the Iranian Azeri population. Asian Pac J Cancer Prev 2015;16:3073–7. https://doi.org/10.7314/apjcp.2015.16.7.3073. ; Dehghan, R, Hosseinpour Feizi, MA, Pouladi, N, Babaei, E, Montazeri, V, Fakhrjoo, A, et al.. Association of p53 (-16ins-pro) haplotype with the decreased risk of differentiated thyroid carcinoma in Iranian-Azeri patients. Pathol Oncol Res 2015;21:449–54. https://doi.org/10.1007/s12253-014-9846-y. ; Fard-Esfahani, P, Fard-Esfahani, A, Fayaz, S, Ghanbarzadeh, B, Saidi, P, Mohabati, R, et al.. Association of Arg194Trp, Arg280His and Arg399Gln polymorphisms in X-ray repair cross-complementing group 1 gene and risk of differentiated thyroid carcinoma in Iran. Iran Biomed J 2011;15:73–8. ; Fard-Esfahani, P, Fard-Esfahani, A, Saidi, P, Fayaz, S, Mohabati, R, Majdi, M. An increased risk of differentiated thyroid carcinoma in Iran with the 677C -> T homozygous polymorphism in the MTHFR gene. Canc Epidemiol 2011;35:56–8. https://doi.org/10.1016/j.canep.2010.10.001. ; Rahimi, M, Fayaz, S, Fard-Esfahani, A, Modarressi, MH, Akrami, SM, Fard-Esfahani, P. The role of Ile3434Thr XRCC7 gene polymorphism in differentiated thyroid cancer risk in an Iranian population. Iran Biomed J 2012;16:218–22. https://doi.org/10.6091/ibj.1078.2012. ; Yazdani, N, Sayahpour, FA, Haghpanah, V, Amiri, P, Shahrabi-Farahani, M, Moradi, M, et al.. Survivin gene polymorphism association with papillary thyroid carcinoma. Pathol Res Pract 2012;208:100–3. https://doi.org/10.1016/j.prp.2011.12.009. ; Hamta, A, Yousefi, M, FAZELI, MAM, Talaei, A, Sadeghi, A. Lack of association between nodular thyroid disease and rs1256049 polymorphism of estrogen receptor beta gene in women from Markazi povince. J Arak Uni Med Sci 2015;18:85–91. ; Feizi, MAH, Tofigh, R, Pouladi, N, Ravanbakhsh, R, Azarfam, P, Montazeri, V. The study of P53 polymorphism in codon 72 in patients with thyroid cancer in a report from East Azerbaijan province Iran. Med J Tabriz Univ Med Sci Health Serv 2013;35:24–9. ; Rahimi, M, Fard-Esfahani, P, Fayaz, S, Fard-Esfahani, A, Modarressi, MH, Akrami, SM. Analysis of G> A change in splicing site of intron 6 of XRCC4 gene in patients with differentiated thyroid cancer (DTC). Int Sportmed J (ISMJ) 2014;17:542–9. ; Younesi, M, Hosseinpour Feizi, M, Pouladi, N. Evaluating the prevalence of plasminogen activator inhibitor-1 gene polymorphism in patients with thyroid tumors from North West of Iran. J Ilam Univ Med Sci 2017;25:166–72. https://doi.org/10.29252/sjimu.25.2.166. ; Abidi, M, Fayaz, S, Esfahani, PF. Association of the Asp1312Gly thyroglobulin gene polymorphism with susceptibility to differentiated thyroid cancer in an Iranian population. Asian Pac J Cancer Prev APJCP 2017;18:503. https://doi.org/10.22034/APJCP.2017.18.2.503. ; Adampourezare, M, Hosseinpourefeizi, M-A, Pouladi, N, Hosseinpourefeizi, E, Azarfam, P. Association of Arg194Trp and Arg399Gln polymorphisms of XRCC1 gene and risk of differentiated thyroid carcinoma in Iranian-Azeri patients. Int J Canc Manag 2017;10. https://doi.org/10.5812/ijcm.5790. ; Ramezani, M, Hedayati, M, Hoseini Asl, S, Tabatabaei, M, Mazani, M, Nasiri, S. Association of vitamin D levels and receptor gene polymorphisms with medullary thyroid cancer. Tehran Univ Med J TUMS Publ 2016;74:274–81. ; Khanlou, ZM, Pouladi, N, Feizi, MH, Pedram, N. Lack of associations of the MDM4 rs4245739 polymorphism with risk of thyroid cancer among Iranian-Azeri patients: a case-control study. Asian Pac J Cancer Prev APJCP 2017;18:1133. ; Maruei-Milan, R, Heidari, Z, Salimi, S. Role of MDM2 309T>G (rs2279744) and I/D (rs3730485) polymorphisms and haplotypes in risk of papillary thyroid carcinoma, tumor stage, tumor size, and early onset of tumor: a case control study. J Cell Physiol 2019;234:12934–40. https://doi.org/10.1002/jcp.27960. ; Abdolahi, F, Dabbaghmanesh, MH, Haghshenas, MR, Ghaderi, A, Erfani, N. A gene-disease association study of IL18 in thyroid cancer: genotype and haplotype analyses. Endocrine 2015;50:698–707. https://doi.org/10.1007/s12020-015-0623-9. ; Abtahi, S, Jahromi, FI, Dabbaghmanesh, MH, Malekzadeh, M, Ghaderi, A. Association between CTLA-4+ 49A> G and–318C> T single-nucleotide polymorphisms and susceptibility to thyroid neoplasm. Endocrine 2018;62:159–65. https://doi.org/10.1007/s12020-018-1663-8. ; Fayaz, S, Karimmirza, M, Tanhaei, S, Fathi, M, Torbati, PM, Fard-Esfahani, P. Increased risk of differentiated thyroid carcinoma with combined effects of homologous recombination repair gene polymorphisms in an Iranian population. Asian Pac J Cancer Prev APJCP 2013;14:6727–31. https://doi.org/10.7314/apjcp.2013.14.11.6727. ; Haghshenas, M, Dabbaghmanesh, M, Miri, A, Ghaderi, A, Erfani, N. Association of PDCD1 gene markers with susceptibility to thyroid cancer. J Endocrinol Invest 2017;40:481–6. https://doi.org/10.1007/s40618-016-0579-5. ; Heidari, Z, Mohammadpour‐Gharehbagh, A, Eskandari, M, Harati‐Sadegh, M, Salimi, S. Genetic polymorphisms of miRNA let7a‐2 and pri‐mir‐34b/c are associated with an increased risk of papillary thyroid carcinoma and clinical/pathological features. J Cell Biochem 2019;120:8640–7. https://doi.org/10.1002/jcb.28152. ; Mohammadpour-Gharehbagh, A, Heidari, Z, Eskandari, M, Aryan, A, Salimi, S. Association between genetic polymorphisms in microRNA machinery genes and risk of papillary thyroid carcinoma. Pathol Oncol Res 2019:1–7. ; Narooie-Nejad, M, Taji, O, Kordi Tamandani, DM, Kaykhaei, MA. Association of CTLA-4 gene polymorphisms-318C/T and+ 49A/G and Hashimoto’s thyroiditis in Zahedan, Iran. Biomed Rep 2017;6:108–12. https://doi.org/10.3892/br.2016.813. ; Khoshi, A, Sirghani, A, Ghazisaeedi, M, Mahmudabadi, AZ, Azimian, A. Association between TPO Asn698Thr and Thr725Pro gene polymorphisms and serum anti-TPO levels in Iranian patients with subclinical hypothyroidism. Hormones (Basel) 2017;16:75–83. ; Zarrin, R, Bagheri, M, Mehdizadeh, A, Ayremlou, P, Faghfouri, AH. The association of FokI and ApaI polymorphisms in vitamin D receptor gene with autoimmune thyroid diseases in the northwest of Iran. Med J Islam Repub Iran 2018;32:4. https://doi.org/10.14196/mjiri.32.4.
- Contributed Indexing: Keywords: Iran; biomarker; genotyping; single nucleotide polymorphisms; thyroid cancer
- Entry Date(s): Date Created: 20210205 Date Completed: 20211228 Latest Revision: 20211228
- Update Code: 20240513
|
